Bisphosphonates as potential adjuvants for patients with cancers of the digestive system

World Journal of Gastroenterology : WJG
Celina AngAndrea Branch

Abstract

Best known for their anti-resorptive activity in bone, bisphosphonates (BPs) have generated interest as potential antineoplastic agents given their pleiotropic biological effects which include antiproliferative, antiangiogenic and immune-modulating properties. Clinical studies in multiple malignancies suggest that BPs may be active in the prevention or treatment of cancer. Digestive tract malignancies represent a large and heterogeneous disease group, and the activity of BPs in these cancers has not been extensively studied. Recent data showing that some BPs inhibit human epidermal growth factor receptor (HER) signaling highlight a potential therapeutic opportunity in digestive cancers, many of which have alterations in the HER axis. Herein, we review the available evidence providing a rationale for the repurposing of BPs as a therapeutic adjunct in the treatment of digestive malignancies, especially in HER-driven subgroups.

References

Oct 3, 1996·The New England Journal of Medicine·P C de GroenK K Wang
Apr 29, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·S P LuckmanM J Rogers
Aug 10, 2000·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·F P CoxonM J Rogers
Nov 30, 2000·Japanese Journal of Clinical Oncology·T OhnishiS Tashiro
Jul 13, 2006·Annals of the New York Academy of Sciences·R Graham G Russell
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 4, 2007·Cancer Immunology, Immunotherapy : CII·Francoise Bouet-ToussaintVéronique Catros
Sep 13, 2007·Medical Oncology·Agustin AvilésJudith Huerta-Guzmán
Aug 9, 2008·Journal of Cancer Research and Therapeutics·V Satya Suresh AttiliH Rajshekar
Sep 9, 2008·Mayo Clinic Proceedings·Matthew T DrakeSuneep Khosla
Oct 17, 2008·The New England Journal of Medicine·Yujin HoshidaTodd R Golub
Jan 2, 2009·The New England Journal of Medicine·Diane K Wysowski
Feb 12, 2009·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takayuki KogureTooru Shimosegawa
Feb 14, 2009·The New England Journal of Medicine·Michael GnantC Marth
Apr 24, 2009·The New England Journal of Medicine·Bo AbrahamsenRichard Eastell
May 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matilde TodaroGiorgio Stassi
May 26, 2009·Biochemical Pharmacology·Antonello A RomaniPaolo Soliani
Jun 13, 2009·International Journal of Cancer. Journal International Du Cancer·Kostantinos ZarogoulidisNikos K Karamanos
Jul 2, 2009·International Journal of Cancer. Journal International Du Cancer·Xudong TangAnh D Le
Sep 18, 2009·Cancer Chemotherapy and Pharmacology·Liliana MontellaSalvatore Del Prete
Dec 18, 2009·Journal of Cellular and Molecular Medicine·Hannah K BrownIngunn Holen
Feb 18, 2010·British Journal of Cancer·P A NewcombJ M Hampton
Apr 17, 2010·Digestive Diseases and Sciences·Dang M NguyenHashem B El-Serag
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rowan T ChlebowskiMarcia L Stefanick
May 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H EidtmannR Coleman
Jun 23, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gad RennertHedy S Rennert
Jun 24, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wei ZhangZhao-You Tang
Aug 12, 2010·JAMA : the Journal of the American Medical Association·Chris R CardwellLiam J Murray
Nov 3, 2010·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yoshio KatamuraKazuaki Chayama
Dec 7, 2010·Lancet·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Study Group
Jan 1, 2010·Drug, Healthcare and Patient Safety·Luca Dalle CarbonareMaria Teresa Valenti
Oct 11, 2011·Cancer Treatment Reviews·Michael Gnant, Philippe Clézardin
Dec 14, 2011·International Journal of Cancer. Journal International Du Cancer·Chris R CardwellLiam J Murray
Jan 5, 2012·Cancer Immunology, Immunotherapy : CII·Matthew R PorembkaPeter Goedegebuure

❮ Previous
Next ❯

Citations

Mar 24, 2018·The Journal of International Medical Research·Hai-Jun WangYong Li
Oct 27, 2018·International Journal of Molecular Sciences·Hongli ZhangYan-Dong Wang
Nov 17, 2020·Frontiers in Cell and Developmental Biology·Zhiwei ShaoAnwen Shao
Jul 3, 2021·International Journal of Molecular Sciences·Zintle Mbese, Blessing A Aderibigbe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
Philippe Clézardin
Annals of Oncology : Official Journal of the European Society for Medical Oncology
D SantiniG Tonini
Seminars in Oncology
Helen L Neville-WebbeRobert E Coleman
© 2021 Meta ULC. All rights reserved